{"prompt": "['Alliance A171601', '9.3.1 Alliance A171601 Reporting Requirements', 'Expedited reporting requirements for adverse events that occuron studies under an IND/IDE', '< 30 Days of the last administration of the investigational agent/intervention 1,2', 'FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSEI EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor (NCI) ANYSerious Adverse Events, whetherornot', 'they are considered: related to the investigational agent(s)/intervention CFR 312.64)', 'An adverse event is considered serious if it results in ANYofthefollowingoutcomes:', '1) Death', '2)', 'A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation ofexis ting hospitalization for > 24', 'hours', '4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5) A congenital anomaly/birth defect.', '6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may', 'be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may', 'require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR', '312.32; ICH E2A and ICHE6).', 'ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the', 'NCI via CTEP-AERS within the timeframes detailed in the table below.', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4 & 5', 'Hospitalization', 'Timeframes', 'Timeframes', 'Timeframes', 'Timeframes', 'Resulting in', 'Hospitalization 24 hrs', '10 Calendar Days', '24-Hour;', 'Not resulting in', '5 Calendar Days', 'Not required', '10 Calendar Days', 'Hospitalization > 24 hrs', 'NOTE Protocol specific exceptions to expeditedreporting of serious adverse events are found in the', 'Specific Protocol Exceptions to Expedited Reporting (SPEER) portion ofthe CAEPR', 'Expedited AE reporting timelines are definedas:', '\"24-Hour; 5 Calendar Days\" - The AEmust initially be reported via CTEP-AERS < 24 hours of', 'learning of the AE, followed by a complete expeditedreport <5 calendar days of the initial 24-hour', 'report.', '\"10 Calendar Days\" - A complete expedited report on the AEmust be submitted < 10 calendar days', 'of learning of the AE.', '1 Serious adverse events that occur more than 30 days after the last administration of investigational', 'agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report <5 calendar days for:', 'All Grade 4, and Grade 5 AEs', 'Expedited 10 calendar day reports for:', 'Grade 2 adverseevents resulting in hospitalization orprolongation of hospitalization', 'Grade 3 adverseevents', '2', 'Forstudies using PET or SPECT IND agents, the AEreporting period is limited to 10 radioactive half-lives,', 'rounded UP to the nearest whole day, after theagent/interventionwas lastadministered Footnote \"1\" above', 'applies after this reporting period.', '39', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '9.3.2 Expedited AE reporting timelines defined', '\"24 hours; 5 calendar days\" - The investigator must initially report the AE via CTEP-AERS', 'VI 24 hours of learning of the event followed by a complete CTEP-AERS report 5 calendar', 'days of the initial 24-hour report.', '\"10 calendar days\" - A complete CTEP-AERS report on the AE must be submitted VI 10', 'calendar days of the investigator learning of the event.', 'Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates hospitalization', '(or prolongation of existing hospitalization) must be reported regardless of attribution and', 'designation as expected or unexpected with the exception of any events identified as', 'protocol-specific expedited adverse event reporting exclusions (see below).', 'Use the NCI protocol number and the protocol-specific patient ID provided during trial', 'registration on all reports.', '9.3.3', 'Additional Instructions or Exclusion to CTEP-AERS Expedited Reporting', 'Requirements', 'All adverse events reported via CTEP-AERS (i.e., serious adverse events) should', 'also be forwarded to your localIRB.', 'Grade 3/4 hematosuppression and hospitalization resulting from such do not', 'require CTEP-AERS, but should be submitted as part of study results. All other grade', '3, 4, or 5 adverse events that precipitate hospitalization or prolong an existing', 'hospitalization must be reported via CTEP-AERS.', 'Reporting of cases of secondary AML/MDS is to be done using the NCI/CTEP', 'Secondary AML/MDS Report Form. New primary malignancies should be reported in', 'Rave.', 'Death due to progressive disease should be reported as Grade 5 \"Disease', 'progression\" in the system organ class (SOC) \"Generaldisorders and administration site', \"conditions.' Evidence that the death was a manifestation of underlying disease (e.g.,\", 'radiological changes suggesting tumor growth or progression: clinical deterioration', 'associated with a disease process) should be submitted.', 'Any death occurring within 30 days of the last dose, regardless of attribution to the', 'investigational agent/intervention requires expedited reporting within 24 hours.', 'Any death occurring greater than 30 days after the last dose of the investigational', 'agent/intervention requires expedited reporting within 24 hours only if it is possibly,', 'probably, or definitely related to the investigational agent/intervention.', 'All new malignancies must be reported via CTEP-AERS whether or not they are', 'thought to be related to either previous or current treatment. All new malignancies', 'should be reported, i.e. solid tumors (including non-melanoma skin malignancies),', 'hematologic malignancies, myelodysplastic syndrome/acute myelogenous leukemia,', 'and in situ tumors. In CTCAE version 5.0, the new malignancies (both second and', 'secondary) may be reported as one of the following: (1) Leukemia secondary to', 'oncology chemotherapy, (2) Myelodysplastic syndrome, (3) Treatment-related', 'secondary malignancy, or (4) Neoplasms benign, malignant and unspecified-other.', 'Whenever possible, the CTEP-AERS reports for new malignancies should include', 'tumor pathology, history or prior tumors, prior treatment/current treatment including', 'duration, any associated risk factors or evidence regarding how long the new', 'malignancy may have been present, when and how the new malignancy was detected,', '40', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}